Related Experiment Video

Updated: Sep 20, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K

LINC00680 modulates docetaxel resistance in breast cancer via the miR-320b/CDKL5 axis

Jia Li1,2, Jing Ke2, Cheng-Lin Qin3

  • 1Department of Thyroid and Breast Surgery, 105860The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

International Journal of Immunopathology and Pharmacology
|June 6, 2022
PubMed

Insights

Long non-coding RNA LINC00680 promotes docetaxel resistance in breast cancer (BC) by regulating the miR-320b/CDKL5 pathway. This finding offers a potential new therapeutic strategy for overcoming BC drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • LINC00680 is increasingly recognized as an oncogenic factor in various cancers.
  • The precise mechanism of LINC00680's role in breast cancer (BC) progression and drug resistance is not fully understood.

Purpose of the Study:

  • To elucidate the mechanism by which LINC00680 contributes to docetaxel resistance in breast cancer.
  • To investigate the regulatory relationship between LINC00680, miR-320b, and CDKL5 in BC cells.

Main Methods:

  • Dual-luciferase reporter assays were employed to confirm the targeting relationship between LINC00680, miR-320b, and CDKL5.
  • Cell Counting Kit-8 (CCK-8) and Transwell assays were used to assess cell proliferation and invasion.
  • LINC00680 knockdown was performed to evaluate its effects on drug resistance-related genes.

Main Results:

  • LINC00680 and Cyclin-Dependent Kinase 5 (CDKL5) protein levels were elevated in response to docetaxel.
  • Knockdown of LINC00680 significantly reduced the proliferation and invasion of docetaxel-resistant BC cells.
  • MiR-320b was identified as a direct target of both LINC00680 and CDKL5, indicating LINC00680 modulates CDKL5 via miR-320b sequestration.

Conclusions:

  • LINC00680 plays a critical role in conferring docetaxel resistance in breast cancer.
  • The miR-320b/CDKL5 pathway is a key mechanism through which LINC00680 promotes drug resistance.
  • Targeting the LINC00680/miR-320b/CDKL5 axis presents a promising therapeutic avenue for overcoming docetaxel resistance in BC.
Keywords:
CDKL5LINC00680ceRNA networkdocetaxel resistancemiR-320b

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.7K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K